Preclinical randomized controlled multicenter trials in translational stroke research

Sergio Amaro, Laura Llull

Abstract

Natalizumab is a humanized monoclonal antibody against alpha-4 integrin (CD49d) that reduces the incursion of circulating leukocytes into the central nervous system across the endothelium (1).